Würzburg

Running trials

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· Source

• Recruiting

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· Source

• Recruiting

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· Phase 3· Source

• Recruiting

  Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  NCT07764978· Phase 3· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· Source

• Recruiting

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· Phase 3· Source

• Recruiting

  A Study of AZD0120 in Autoimmune Diseases

  NCT07295847· Phase 1/2· Source

• Recruiting

  A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· Phase 1/2· Source

• Recruiting

  A Non-interventional, Prospective Study With Benralizumab

  NCT06422078· Source

• Recruiting

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· Source

• Recruiting

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· Phase 1/2· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Source

• Recruiting

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· Phase 3· Source

• Recruiting

  AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  NCT06106945· Phase 1/2· Source

• Recruiting

  PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

  NCT05573893· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

  NCT03164616· Phase 3· Source

• Active, not recruiting

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· Phase 3· Source

• Active, not recruiting

  Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

  NCT01933932· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma3 recruiting
• Amyloidosis2 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

  NCT07224373· Phase 1· Source

• Completed

  ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· Source

• Completed

  REported Outcomes in COPD With Trixeo in Real worlD in Germany

  NCT05311306· Source

• Completed

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· Phase 3· Source

• Completed

  AZD9291 First Time In Patients Ascending Dose Study

  NCT01802632· Phase 1/2· Source